Sign up United Kingdom
Feedback plc (LON:FDBK)

Feedback plc (LON:FDBK)

Share Price
1.80 p
0.122 (7.28 %)
Market Cap
£5.06 m
Proactive Investors - Run By Investors For Investors

Feedback plc RNS Release

Presentation at RSNA 2017

RNS Number : 1585X
Feedback PLC
22 November 2017

Presentation at RSNA 2017


Cambridge, UK - 22 November 2017: Feedback plc ("Feedback" or the "Company") (AIM: FDBK), the specialist medical imaging technology company, announces that Dr Balaji Ganeshan will be presenting at the 103rd Scientific Assembly and Annual Meeting of the Radiological Society of North America ("RSNA 2017") taking place from 26 November to 1 December 2017 in Chicago (IL), USA.


The details for the oral presentation on the study undertaken at the Institute of Nuclear Medicine, University College London, UK are as follows:


Date and session time: Wednesday 29 November at 15:00 - 16:00 CST

Title: Texture Analysis of 68Ga-DOTATATE Positron Emission Tomography and Computed Tomography Images as a Prognostic Biomarker in Adults with Neuro-Endocrine Cancers Treated with 177Lu-DOTATATE

Abstract number: SSM13-06

Session: Molecular Imaging (Analysis and Quantification)

Room: S504C

Presenter: Balaji Ganeshan, PhD


Two additional papers co-authored by Dr Balaji Ganeshan will be presented at RSNA 2017; one by Seoul National University and University College London focused on liver cancer (abstract SSK07-05), and one by Cambridge University, the University of Rome and University College London focused on ischemic stroke (abstract SSQ15-02).  Overall, RSNA 2017 is expected to include at least 18 scientific paper presentations featuring TexRAD® Computed Tomography Texture Analysis (CTTA) and Magnetic Resonance Texture Analysis (MRTA), many of which have won awards in this year's RSNA categories.  Further information can be found at


Dr Balaji Ganeshan, Director of New Business at Feedback plc, said: "RSNA is the premier global event for radiologists and the increasing focus on our TexRAD® technology is encouraging. As seen in previous years, our renowned customers will highlight multiple TexRAD® presentations across various disease indications, further emphasising the significance of our technology across the healthcare industry.  We look forward to discussing TexRAD® with this year's RSNA delegates."


TexRAD® is the Company's patented quantitative image texture analysis technology for diagnostic radiological scans.  The technology has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer, or other disease indications, and is currently installed in over 40 of the world's leading research institutions across Europe, North America, Asia and Australasia.  By analysing the texture features in computerised tomography (CT) scans, magnetic resonance images (MRI) and positron emission tomography scans (PET/CT), TexRAD®'s quantitative imaging capabilities provide clinicians with additional, visually imperceptible information to make better decisions in order to improve patient outcomes.  


TexRAD® research to date has shown great potential in many different oncological and non-oncological sites.  In particular, the papers being presented at RSNA 2017 focus on liver, pancreatic, kidney, cervical, oral, genitourinary, head & neck, thyroid, neuroendocrine and endometrial cancers, as well as gastrointestinal stromal tumours, gliomas, thymic-epithelial neoplasms and carotid-plaques.  On 20 November 2017, Feedback announced the CE marked release of TexRAD® Lung, a "software only" Class 1 medical device, to help advance lung cancer diagnosis.  Further information on the TexRAD® technology can be found at


- Ends -



Notes to editors


About Feedback plc

Feedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and improved workflows for practitioners involved in medical research and treating patients. TexRAD®, the Company's patented quantitative image texture analysis technology, has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 40 of the world's leading research institutions across Europe, North America, Asia and Australasia. The Cadran platform provides a suite of medical imaging tools for decision support. The Cadran range includes the picture archiving communication system (PACS) to provide decision support for scan analysis, diagnostic workstations which provide secure remote access to view scans on demand, and products to securely share and transport patient data. Visit


For further information, please contact:


Feedback plc

Dr Alastair Riddell, Chairman

Lara Mott, Investor Relations


Tel: 01954 718072

[email protected]


This information is provided by RNS
The company news service from the London Stock Exchange

Feedback plc Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use